Participated · Series A · May 2024

Backpack Healthcare (formerly Youme Healthcare) operates an online pediatric mental-health platform that combines an AI-powered emotion-monitoring app with live teletherapy delivered by licensed clinicians. The company’s algorithms assess mood signals and automatically match young users to therapists who specialize in their needs, creating individualized treatment plans. Beyond one-on-one pediatric sessions, Backpack offers family therapy, medication management, and live parent-training webinars covering topics such as cyberbullying and substance abuse. Interactive digital tools and gamified activities are used to keep children engaged and encourage consistent participation in care. With its newly secured capital, management plans to enhance the technology stack, broaden geographic reach, and deepen its teletherapy service portfolio. Equity and inclusion remain a stated priority, underscored by the addition of Robert Johnson, ESQ, to the advisory board to guide inclusive growth initiatives.

Participated · Series A · Jan 2024

Lykos Therapeutics (formerly MAPS Public Benefit Corporation) develops investigational MDMA-assisted therapy to treat post-traumatic stress disorder (PTSD). The company has completed two randomized, double-blind, placebo-controlled Phase 3 trials (MAPP1 and MAPP2) that met primary and secondary endpoints and has submitted a new drug application (NDA) to the U.S. Food and Drug Administration. If approved, the therapy would be the first psychedelic-assisted therapy for PTSD; Lykos is preparing regulatory and pre-launch activities to integrate the therapy into the healthcare system. Lykos rebranded from MAPS PBC and is transitioning from a research-stage organization to a for-profit public benefit corporation focused on commercialization; it was founded by the non-profit MAPS in 2014. The company notes Breakthrough Therapy designation for MDMA since 2017 and has requested Priority Review of its NDA, while also stating that MDMA-assisted therapy has not been approved and its safety and efficacy have not been established. The recent financing will support regulatory, pre-launch and commercialization preparations.